Economic evaluation of Zepatier for the management of HCV in the Italian scenario [0.03%]
Zepatier在意大利HCV患者中的经济学评价研究摘要
F R Rolli,M Ruggeri,F Kheiraoui et al.
F R Rolli et al.
Background: Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections. ...
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany [0.03%]
德国IQWiG机构进行早期药物效益评估时所采用方法中的几点方法学问题
Matthias Herpers,Charalabos-Markos Dintsios
Matthias Herpers
Background: The decision matrix applied by the Institute for Quality and Efficiency in Health Care (IQWiG) for the quantification of added benefit within the early benefit assessment of new pharmaceuticals in Germany with...
People's perception and cost-effectiveness of home confinement during an influenza pandemic: evidence from the French case [0.03%]
人们的认知及在家隔离的成本效益：来自法国的证据
Caroline Orset
Caroline Orset
In France, home confinement is not a common preventive measure against an influenza pandemic, although it is used around the world. Based on a stated method approach, we analyze the attitude that the French would adopt if this measure were ...
Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students [0.03%]
增强Quit-and-Win戒烟项目以提高其成本效益——一项针对大学生的研究
Jonah Popp,John A Nyman,Xianghua Luo et al.
Jonah Popp et al.
Objectives: We conducted a cost-effectiveness analysis and model-based cost-utility and cost-benefit analysis of increased dosage (3 vs. 1 consecutive contests) and enhanced content (supplemental smoking-cessation counsel...
The economic impact of multiple sclerosis to the patients and their families in Norway [0.03%]
挪威多发性硬化症患者的经济影响及其家庭的影响
B Svendsen,N Grytten,L Bø et al.
B Svendsen et al.
Background: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objectiv...
Examining unpriced risk heterogeneity in the Dutch health insurance market [0.03%]
荷兰健康保险市场中未定价的风险异质性分析
A A Withagen-Koster,R C van Kleef,F Eijkenaar
A A Withagen-Koster
A major challenge in regulated health insurance markets is to mitigate risk selection potential. Risk selection can occur in the presence of unpriced risk heterogeneity, which refers to predictable variation in health care spending not refl...
Future unrelated medical costs need to be considered in cost effectiveness analysis [0.03%]
成本效益分析需纳入未来未相关的医疗费用问题
Pieter van Baal,Alec Morton,David Meltzer et al.
Pieter van Baal et al.
New medical technologies that prolong life result in additional health care use in life years gained. Some of these costs in life years gained are considered to be related to the intervention while other costs are considered unrelated. Here...
Floortje van Nooten,Jan Busschbach,Michel van Agthoven et al.
Floortje van Nooten et al.
Preferences for home- and community-based long-term care services in Germany: a discrete choice experiment [0.03%]
德国居家和社区长期护理服务偏好：一项离散选择实验研究
T Lehnert,O H Günther,A Hajek et al.
T Lehnert et al.
Background: Most people prefer to "age in place" and to remain in their homes for as long as possible even in case they require long-term care. While informal care is projected to decrease in Germany, the use of home- and...
Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach [0.03%]
基于决策分析模型的提高治疗率对呼吸道过敏亚临 床免疫治疗（SCIT）的成本效益的影响研究
Ann-Kathrin Richter,Ludger Klimek,Hans F Merk et al.
Ann-Kathrin Richter et al.
Background: Specific immunotherapy is the only causal treatment in respiratory allergy. Due to high treatment cost and possible severe side effects subcutaneous immunotherapy (SCIT) is not indicated in all patients. Never...